Literature DB >> 9294784

Molecular pharmacology of somatostatin receptor subtypes.

Y C Patel1.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9294784     DOI： 10.1007/BF03350317

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  153 in total

1.  Differential expression of somatostatin receptor subtypes in brain.

Authors:  C D Breder; Y Yamada; K Yasuda; S Seino; C B Saper; G I Bell
Journal:  J Neurosci       Date:  1992-10       Impact factor: 6.167

2.  17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo.

Authors:  H A Visser-Wisselaar; C J Van Uffelen; P M Van Koetsveld; E G Lichtenauer-Kaligis; A M Waaijers; P Uitterlinden; D M Mooy; S W Lamberts; L J Hofland
Journal:  Endocrinology       Date:  1997-03       Impact factor: 4.736

3.  Expression of five somatostatin receptor mRNAs in the human brain and pituitary.

Authors:  V S Thoss; J Pérez; A Probst; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 4.  Molecular biology of somatostatin receptor subtypes.

Authors:  Y C Patel; M Greenwood; R Panetta; N Hukovic; S Grigorakis; L A Robertson; C B Srikant
Journal:  Metabolism       Date:  1996-08       Impact factor: 8.694

5.  Development of a selective agonist at the somatostatin receptor subtype sstr1.

Authors:  G Liapakis; C Hoeger; J Rivier; T Reisine
Journal:  J Pharmacol Exp Ther       Date:  1996-03       Impact factor: 4.030

6.  G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells.

Authors:  Y F Liu; K H Jakobs; M M Rasenick; P R Albert
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

7.  Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.

Authors:  L J Hofland; P M van Koetsveld; M Waaijers; J Zuyderwijk; W A Breeman; S W Lamberts
Journal:  Endocrinology       Date:  1995-09       Impact factor: 4.736

8.  Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells.

Authors:  C Vidal; I Rauly; M Zeggari; N Delesque; J P Esteve; N Saint-Laurent; N Vaysse; C Susini
Journal:  Mol Pharmacol       Date:  1994-07       Impact factor: 4.436

9.  Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995.

Authors:  Y Fujii; T Gonoi; Y Yamada; K Chihara; N Inagaki; S Seino
Journal:  FEBS Lett       Date:  1994-11-28       Impact factor: 4.124

10.  Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. II. An increase in potassium conductance initiates somatostatin-induced inhibition of prolactin secretion.

Authors:  B D Koch; A Schonbrunn
Journal:  J Biol Chem       Date:  1988-01-05       Impact factor: 5.157
View more
  50 in total

Review 1.  The therapeutic value of somatostatin and its analogues.

Authors:  S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 2.  Synthetic peptides and their non-peptidyl mimetics in endocrinology: from synthesis to clinical perspectives.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

Review 3.  Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.

Authors:  Rosa Maria Paragliola; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Authors:  A Nagy; A V Schally; G Halmos; P Armatis; R Z Cai; V Csernus; M Kovács; M Koppán; K Szepesházi; Z Kahán
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Role of somatostatin receptors on gastric acid secretion in wild-type and somatostatin receptor type 2 knockout mice.

Authors:  Laura Piqueras; Vicente Martínez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-20       Impact factor: 3.000

6.  Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway.

Authors:  Chun-Hui Wang; Cheng-Wei Tang; Chun-Lun Liu; Li-Ping Tang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.

Authors:  L Yang; S C Berk; S P Rohrer; R T Mosley; L Guo; D J Underwood; B H Arison; E T Birzin; E C Hayes; S W Mitra; R M Parmar; K Cheng; T J Wu; B S Butler; F Foor; A Pasternak; Y Pan; M Silva; R M Freidinger; R G Smith; K Chapman; J M Schaeffer; A A Patchett
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Synthesis, in vitro biological activity, hydrolytic stability and docking of new analogs of BIM-23052 containing halogenated amino acids.

Authors:  Dancho Danalev; Desislava Borisova; Spaska Yaneva; Maya Georgieva; Anelia Balacheva; Tatyana Dzimbova; Ivan Iliev; Tamara Pajpanova; Zdravka Zaharieva; Ivan Givechev; Emilia Naydenova
Journal:  Amino Acids       Date:  2020-11-19       Impact factor: 3.520

Review 9.  The beta-D-glucose scaffold as a beta-turn mimetic.

Authors:  Ralph F Hirschmann; K C Nicolaou; Angie R Angeles; Jason S Chen; Amos B Smith
Journal:  Acc Chem Res       Date:  2009-10-20       Impact factor: 22.384

10.  Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.

Authors:  Hanna Pisarek; Tomasz Stepień; Robert Kubiak; Edyta Borkowska; Marek Pawlikowski
Journal:  Thyroid Res       Date:  2009-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.